Yousif Capital Management LLC Sells 160 Shares of Humana Inc. (NYSE:HUM)

Yousif Capital Management LLC reduced its stake in Humana Inc. (NYSE:HUM) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,049 shares of the insurance provider’s stock after selling 160 shares during the period. Yousif Capital Management LLC’s holdings in Humana were worth $5,340,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC increased its stake in Humana by 261,025.1% in the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock valued at $2,340,660,000 after acquiring an additional 738,701 shares during the last quarter. FMR LLC boosted its holdings in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Humana by 55.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after purchasing an additional 214,535 shares during the last quarter. Retirement Systems of Alabama increased its position in shares of Humana by 735.9% during the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Finally, Pzena Investment Management LLC raised its holdings in shares of Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.32% of the stock is currently owned by insiders.

Humana Stock Down 3.8 %

Shares of Humana stock opened at $279.63 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.67 billion, a P/E ratio of 24.77, a PEG ratio of 2.21 and a beta of 0.56. The firm’s 50 day moving average price is $275.01 and its 200-day moving average price is $299.65. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Barclays boosted their target price on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 22nd. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company decreased their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and an average target price of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.